S-1: Exicure Pivots Strategy with Biotech Asset Sales and New Ventures, Faces Going Concern Doubt Amidst Capital Raises

Exicure, Inc. is undergoing a significant strategic shift, divesting historical biotechnology assets to focus on new ventures including a blood cancer clinical trial and Korean entertainment and renewable energy businesses, while actively raising capital to address substantial doubt about its ability to continue as a going concern.

Summary

• Exicure, Inc. has transitioned from an early-stage biotechnology company, halting all research and development activities in September 2022 and selling its historical biotechnology intellectual property and other assets.
• The company acquired GPCR Therapeutics USA Inc. (GPCR USA) for $1.6 million on January 19, 2025, gaining a Phase 2 clinical trial for GPC-100 (Burixafor) in Multiple Myeloma patients, with results expected in Q4 2025.
• A new wholly-owned South Korean subsidiary, KC Creation Co., Ltd., was formed on March 26, 2025, to pursue 'K-Roof' (Korean entertainment content) and 'Construction Business' (eco-friendly renewable energy infrastructure).
• Exicure reported a net income of $3.0 million for the three months ended March 31, 2025, primarily due to a $6.0 million gain from the early termination of its Chicago office lease.
• For the year ended December 31, 2024, the company reported a net loss of $9.7 million, an improvement from a $16.9 million net loss in 2023.
• Cash and cash equivalents stood at $10.4 million as of March 31, 2025, down from $12.5 million at December 31, 2024.
• The company raised approximately $14.0 million through common stock purchase agreements in late 2024 and early 2025, including $10.0 million from HiTron Systems Inc., $2.0 million from SangSangIn Investment & Securities Co., Ltd., $0.405 million from MIRTO Co., LTD., and $1.6 million from Shin Chang Partners and RMS0718 Co., Ltd.
• Exicure converted $1.0 million in promissory notes from DGP Co., Ltd. and an individual investor into 339,214 shares of common stock in September 2024.
• The company recognized $0.5 million in revenue in 2024 from a patent license agreement for cavrotolimod for hepatitis treatment, with modest future royalties expected.
• An investment in convertible notes receivable totaling $2.0 million was fully impaired in 2023, as the issuer appears to have ceased operations and has not responded to redemption requests.

Sentiment

Score: 2

Explanation: The company faces 'substantial doubt about its ability to continue as a going concern,' has a history of significant losses, and relies heavily on future capital raises. While new ventures and a one-time gain offer some positive notes, the fundamental financial instability and high operational risks, coupled with management's limited U.S. public company experience, indicate a very high-risk profile.

Positives

• Achieved a net income of $3.0 million in Q1 2025, primarily driven by a $6.0 million gain from early lease termination.
• Successfully raised approximately $14.0 million through multiple common stock purchase agreements in late 2024 and early 2025, providing much-needed capital.
• Acquired GPCR USA, bringing an ongoing Phase 2 clinical trial for GPC-100 in Multiple Myeloma patients, with results anticipated in Q4 2025.
• Established KC Creation Co., Ltd. to diversify into potentially high-growth sectors like Korean entertainment content and eco-friendly renewable energy infrastructure.
• Reduced net loss from $16.9 million in 2023 to $9.7 million in 2024, reflecting significant cost reductions and a shift in operational focus.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient liquidity and ongoing negative cash flows from operations.
• The positive net income in Q1 2025 is largely attributable to a one-time gain from lease termination, not sustainable operational profitability.
• The company has a history of significant operating losses, with an accumulated deficit of $196.254 million as of March 31, 2025.
• An investment in convertible notes receivable totaling $2.0 million was fully impaired, as the issuer is unresponsive and appears to have ceased operations.
• The company has no current source of significant, ongoing revenue or committed financing, relying heavily on future equity offerings.
• The company has faced numerous Nasdaq listing deficiency notices, including for minimum bid price, stockholders' equity, and corporate governance, leading to a mandatory panel monitor for one year from December 20, 2024.
• The ability to use net operating loss carryforwards is severely limited due to past ownership changes and the discontinuation of the original business, subjecting them to a zero limitation under IRC Section 382(c).

Risks

• Exploration of strategic alternatives may not be successful, timely, or generate anticipated benefits for stockholders.
• Substantial additional funding is needed in the very near term, which may not be available on acceptable terms, potentially leading to bankruptcy or cessation of operations.
• Limited ability for investors to assess operations conducted within private subsidiaries, as financial statements are consolidated, potentially obscuring financial distress of individual subsidiaries.
• Uncertainty regarding the recognition of royalties or license payments from historical biotechnology intellectual property and other assets following their sale.
• Inability to redeem the $2.09 million investment in convertible notes receivable, as the issuer appears to have ceased operations.
• Controlling stockholders, executive officers, and board members have limited experience controlling or governing a U.S. public company, potentially impacting compliance and risk management.
• Potential turnover of senior management and board members could create significant continuity risks and impair the ability to raise capital and execute strategic alternatives.
• Failure to comply with all applicable laws, particularly challenging given recent turnover, reductions in force, and limited resources.
• Common stock may be delisted from Nasdaq due to failure to meet listing requirements, negatively impacting price, liquidity, and access to capital markets.
• The company's common stock price has been, and is likely to continue to be, highly volatile.
• Raising additional funds by issuing securities may cause dilution to existing stockholders.
• Reduced reporting requirements as a smaller reporting company may make common stock less attractive to some investors.
• Anti-takeover provisions in charter documents and under DGCL could make an acquisition more difficult and prevent management replacement.
• Designation of the Court of Chancery of the State of Delaware as the sole forum for certain actions may limit stockholders' ability to obtain a favorable judicial forum.
• FINRA sales practice requirements for low-priced securities may limit stockholders' ability to buy and sell the stock.
• Limited research coverage by securities and industry analysts could negatively impact stock price and trading volume.
• Physical separation and time differences among leadership, accounting, and operations (U.S. and South Korea) require careful coordination, with any lapse potentially leading to material misstatements and liability.
• Internal computer systems or those of contractors/consultants may fail or suffer security breaches, leading to business disruption, data loss, or intellectual property compromise.

Future Outlook

The company plans to focus on exploring growth through acquisitions and transactions with potential partners, particularly in Asia, and diversifying into Korean entertainment content ('K-Roof Business') and eco-friendly renewable energy infrastructure ('Construction Business'). It will also continue to seek additional financing to support these activities. GPCR USA aims to complete GPC-100 administration to 20 patients in Q2 2025 and announce clinical trial results in Q4 2025, with commercialization expected around 2028-2029, pending further testing and FDA approval.

Management Comments

• Management believes that the company's existing cash and cash equivalents are insufficient to continue to fund its operating expenses, and additional funding is needed.
• Management believes that the company's current liquidity is not sufficient to continue to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The Board will consider any promising transactions that it believes can create value for stockholders, including in industries unrelated to historical operations.
• The company's board and management do not have meaningful experience executing strategic endeavors in the U.S. public markets.

Industry Context

Exicure's shift from a specialized biotechnology focus to a diversified portfolio including a clinical-stage drug candidate (GPC-100 for blood cancer) and non-biotech ventures (Korean entertainment and renewable energy) represents a significant departure from traditional biotech industry trends. While the biotech sector often sees companies exploring strategic partnerships or acquisitions for drug development, Exicure's move into unrelated industries like entertainment and construction is highly unusual. This diversification strategy, particularly with a focus on Korean markets and partnerships, aligns with the background and relationships of its new controlling stockholders and management, who have limited experience with U.S. public companies. The ongoing Phase 2 clinical trial for GPC-100 places GPCR USA within the competitive landscape of CXCR4 inhibitors, alongside companies like Sanofi, BioLineRx, and X4 Pharmaceuticals, but its broader strategic pivot makes direct industry comparisons challenging.

Comparison to Industry Standards

• GPCR USA's GPC-100 is in Phase 2 clinical trials for stem cell mobilization in Multiple Myeloma patients, competing with other CXCR4 inhibitors like Sanofi's Plerixafor, BioLineRx's Motixafortide, and X4 Pharmaceuticals' Mavorixafor, which are at various stages of development or commercialization.
• The company's financial position, marked by substantial accumulated deficits and a 'going concern' warning, is significantly below the financial health typically expected of established public companies in the biotechnology or other industries it is entering.
• The reliance on frequent capital raises through private placements and debt-for-equity exchanges, coupled with missed registration deadlines and associated liquidated damages, indicates a financial instability that is not standard for well-capitalized public companies.
• The rapid and extensive turnover in the board and senior management, and the stated lack of experience of new leadership with U.S. public company governance, deviates from best practices for corporate stability and investor confidence in established markets.

Management Changes

Corporate Governance

Legal Proceedings

• A securities class action lawsuit (Colwell v. Exicure, Inc. et al.) alleging materially false/misleading statements related to clinical programs was settled for $5.625 million, fully covered by insurance, but the company recorded a $1.1 million accrual for the unsatisfied portion of its $2.5 million self-insured retainer.
• Three shareholder derivative lawsuits (Puri v. Giljohann, et al.; Sim v. Giljohann, et al.; Stourbridge Investments LLC v. Exicure, Inc. et al.) and a demand letter are currently stayed, with the company engaged in settlement discussions regarding alleged breaches of fiduciary duties and corporate waste.
• A former employee filed a complaint on October 3, 2023, related to their separation; the matter is in the discovery phase after failing to settle at a conference on July 17, 2024.

Related Party Transactions

• HiTron Systems Inc. is a beneficial owner of 52.8% of common stock, and its CEO (Andy Yoo), Vice President (Ho Jung John), and Chief Strategy Officer (Seung Ik Baik) are also company directors/officers. Six out of seven current directors were delegated by HiTron.
• DGP Co., Ltd. (DGP), an affiliate of former controlling stockholder CBI USA, Inc., collectively owns 10.4% of outstanding common stock. DGP provided a $700,000 loan in June 2024, which was converted into 237,223 shares of common stock in September 2024 as a troubled debt restructuring.
• The company paid $27,000 to CBI USA and accrued $191,000 to DGP for liquidated damages due to missed registration statement filing deadlines, though DGP waived its $191,000 penalty in February 2025.
• The company entered into a Consulting Agreement with Alta Companies Ltd. (Paul Kang's entity, former CEO and director) in February 2025, agreeing to pay an initial fee of $99,000 and a monthly fee of $12,500 for transitional consulting services.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings, as well as potential loss of investment due to the 'going concern' doubt and Nasdaq delisting risk.
• Employees, particularly senior management, have experienced significant turnover and face continuity risks, though new employment agreements for the CEO and CFO include increased salaries and severance packages.
• Customers and suppliers of GPCR USA and the new KC Creation businesses may experience changes in operational focus and partnerships as the company pivots its strategy.
• Creditors, particularly holders of the impaired convertible notes receivable, face uncertainty regarding the recovery of their investments.
• Regulatory bodies, specifically Nasdaq and the SEC, are actively monitoring the company's compliance with listing requirements and reporting obligations.

Next Steps

• Complete administration of GPC-100 to 20 patients in the Phase 2 clinical trial during Q2 2025.
• Announce clinical trial results for GPC-100 during Q4 2025.
• Continue actively pursuing strategic alternatives, including private company acquisitions, raising additional capital, strategic partnerships, and other arrangements.
• Further develop and commercialize GPCR's technologies related to GPC-100, including potential milestone payments upon achievement of specific clinical trial, marketing authorization, and net sales events.
• Develop infrastructure based on eco-friendly renewable energy and diversify into Korean entertainment content through KC Creation Co., Ltd.
• Continue redemption attempts for the $2.0 million investment in convertible notes receivable.
• Work through alleged discovery deficiencies and anticipate deposing the plaintiff and witnesses in the former employee litigation.

Key Dates

Recommendation

Keywords

Biotechnology, SEC Filing, S-1 Registration, Strategic Alternatives, Capital Raise, Going Concern, Clinical Trials, GPC-100, Multiple Myeloma, Korean Entertainment, Renewable Energy, Nasdaq Listing, Corporate Governance, Risk Factors, Financial Performance, Dilution, Intellectual Property, Management Changes